Determine Long-Term Safety and Tolerability of Pregabalin in Patients With Anxiety Disorders.
Phase 3
Completed
- Conditions
- Anxiety Neuroses
- Registration Number
- NCT00150449
- Lead Sponsor
- Pfizer
- Brief Summary
Determine long-term safety and tolerability of pregabalin in patients with anxiety disorders.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 511
Inclusion Criteria
- Must have completed the double-blind portion of the preceding trial
- Completed any protocol specified withdrawal phase and follow-up visits.
Read More
Exclusion Criteria
- Patient cannot participate if they experienced a serious adverse event or a nonserious, but medically significant adverse event during the preceding efficacy study that was judged to be related to the study medication.
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Safety Tolerability
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Pfizer Investigational Site